Advancing vision. Elevating care.
RenVia exists because the next era of ocular surface care deserves a commercialization partner that operates with the standard of a premium biotech — not a distributor.
We were created to help physicians access the innovation patients deserve.
Regenerative biology is reshaping ocular surface care. Lyophilization, in particular, has unlocked the ability to bring amniotic membrane technology into more practices than ever before — without cold-chain complexity.
RenVia was founded to make that technology accessible. As a trusted U.S. commercialization partner for Oculus Biologics and the XcellerEYES product line, we bridge regenerative science and clinical workflow — providing the education, logistics, and clinical support practices need to integrate XcellerEYES with confidence.
We believe in clinical credibility over hype. In premium operations over generic distribution. And in partnerships that scale alongside your practice.
Mission
Help eye care professionals improve patient outcomes through advanced regenerative technologies.
Vision
A future where every clinician has access to regenerative biology that elevates the standard of care.
Approach
Clinical credibility first. Premium partnership. Simplicity for practices that need to scale.
Built on the science of Oculus Biologics.
RenVia is a trusted U.S. commercialization partner for Oculus Biologics — a leader in regenerative biology and the developer of XcellerEYES.
Ready to elevate ocular surface care?
Tell us about your practice. A RenVia clinical specialist will reach out within one business day to discuss product evaluation, ordering, and clinical support.
- Personalized product evaluation
- Clinical onboarding & training
- Dedicated commercial support
- Streamlined ordering through your existing workflow